Sitemap | Feedback

Advanced search

Journal of Case Reports

Massive Hydrothorax Following External Jugular Vein Cannulation in an Infant

Stefania Franzini¹, Emanuela Paradiso¹, Claudia Casiraghi¹, Stefano Scalia Catenacci¹, Giuseppe Sofi¹, Ernesto Leva²

¹Anesthesia and Pediatric Intensive Care Unit and ²Department of Pediatric Surgery, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.

Corresponding Author:
Dr. Stefania Franzini Email: stefania.franzini@tiscali.it

Received: 11-FEB-2019

Accepted: 08-MAY-2019

Published Online: 15-MAY-2019

DOI:	http://dx.doi.org/10.17659/01.2019.0026

Abstract

Background: Complications associated with central vein cannulation (CVC) in the adult and pediatric population are well known. On the contrary, adverse events following peripheral vein cannulation (PVC) are rare. Case Report: A 13 months infant was admitted to the Emergency Department for bowel obstruction and severe dehydration. A right external jugular vein access was positioned and fluid infusions started. After few hours the infant became tachypnoic, tachycardic with high lactate levels. An X-ray of the abdomen showed air-fluid levels. The infant was successfully resuscitated following cardiac arrest. A lung ultrasound and a chest X-ray showed a massive right pleural effusion. A chest tube was placed in the right pleural cavity and clear fluid under pressure was drained, which was almost the amount of fluid infused through the right PVC, with stabilization of the general condition. Conclusion: Cannulation of the external jugular vein in infants may result in severe respiratory and cardiac complications and always require adequate monitoring of the patient.

Keywords :

Central Venous Catheterization, Heart Arrest, Hydrothorax, Jugular Veins, Peripheral Catheterization, Pleural Effusion.

Article Options

FULL TEXT
ABSTRACT
PDF

PRINTER FRIENDLY VERSION

Search PubMed for

Search Google Scholar for

Article Statistics

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

Last updated on Jun 15, 2025